Trial Profile
A study to evaluate patient outcomes in the Belgian medical need program of bevacizumab fro the treatment of recurrent primary or secondary glioblastoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 16 Mar 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- 16 Mar 2016 New trial record